Modified TPEx as First-line Treatment for Recurrent and/or Metastatic Head and Neck Cancer

Biomedicines, Free Full-Text

Frontiers Identification of a Prognostic Clinical Score for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Systemic Therapy Including Cetuximab

Targeted therapy for head and neck cancer: signaling pathways and clinical studies

Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer, BMC Cancer

Safety and preliminary activity of pembrolizumab‑carboplatin‑paclitaxel in heavily pretreated and/or fragile patients with PDL1‑positive recurrent/metastatic head and neck cancer

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised

Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era, Journal of Translational Medicine

Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies

First‐line cetuximab + platinum‐based therapy for recurrent/metastatic head and neck squamous cell carcinoma: A real‐world observational study—ENCORE - Le Tourneau - 2023 - Cancer Reports - Wiley Online Library

Cancers, Free Full-Text

Modified TPEx as First-line Treatment for Recurrent and/or Metastatic Head and Neck Cancer

PDF) First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2